Exact Mass: 445.2828084
Exact Mass Matches: 445.2828084
Found 84 metabolites which its exact mass value is equals to given mass value 445.2828084
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Dynorphin B (10-13)
Dynorphin B (10-13) is fraction of Dynorphin B with only Lys-Val-Val-Thr peptide chain. Dynorphin B is an agonist of nuclear opioid receptors coupling nuclear protein Kinase C activation to the transcription of cardiogenic genes in GTR1 embryonic stem cells. Dynorphin B is a form of dynorphin.Dynorphins are a class of opioid peptides that arise from the precursor protein prodynorphin. When prodynorphin is cleaved during processing by proprotein convertase 2 (PC2), multiple active peptides are released: dynorphin A, dynorphin B, and a/b-neo-endorphin. Depolarization of a neuron containing prodynorphin stimulates PC2 processing, which occurs within synaptic vesicles in the presynaptic terminal. Occasionally, prodynorphin is not fully processed, leading to the release of "big dynorphin."This 32-amino acid molecule consists of both dynorphin A and dynorphin B.Dynorphin A, dynorphin B, and big dynorphin all contain a high proportion of basic amino acid residues, in particular lysine and arginine (29.4\\%, 23.1\\%, and 31.2\\% basic residues, respectively), as well as many hydrophobic residues (41.2\\%, 30.8\\%, and 34.4\\% hydrophobic residues, respectively). Although dynorphins are found widely distributed in the CNS, they have the highest concentrations in the hypothalamus, medulla, pons, midbrain, and spinal cord. Dynorphins are stored in large (80-120 nm diameter) dense-core vesicles that are considerably larger than vesicles storing neurotransmitters. These large dense-core vesicles differ from small synaptic vesicles in that a more intense and prolonged stimulus is needed to cause the large vesicles to release their contents into the synaptic cleft. Dense-core vesicle storage is characteristic of opioid peptides storage. The first clues to the functionality of dynorphins came from Goldstein et al. in their work with opioid peptides. The group discovered an endogenous opioid peptide in the porcine pituitary that proved difficult to isolate. By sequencing the first 13 amino acids of the peptide, they created a synthetic version of the peptide with a similar potency to the natural peptide. Goldstein et al. applied the synthetic peptide to the guinea ileum longitudinal muscle and found it to be an extraordinarily potent opioid peptide. The peptide was called dynorphin (from the Greek dynamis=power) to describe its potency. Dynorphins exert their effects primarily through the κ-opioid receptor (KOR), a G-protein-coupled receptor. Two subtypes of KORs have been identified: K1 and K2. Although KOR is the primary receptor for all dynorphins, the peptides do have some affinity for the μ-opioid receptor (MOR), d-opioid receptor (DOR), N-methyl-D-aspartic acid (NMDA)-type glutamate receptor. Different dynorphins show different receptor selectivities and potencies at receptors. Big dynorphin and dynorphin A have the same selectivity for human KOR, but dynorphin A is more selective for KOR over MOR and DOR than is big dynorphin. Big dynorphin is more potent at KORs than is dynorphin A. Both big dynorphin and dynorphin A are more potent and more selective than dynorphin B (Wikipedia). Dynorphin B (10-13) is fraction of Dynorphin B with only Lys-Val-Val-Thr peptide chain.
Ile Val Ser Lys
Ile Lys Ser Val
Ile Lys Val Ser
Ile Ser Lys Val
Ile Ser Val Lys
Ile Val Lys Ser
Lys Ile Ser Val
Lys Ile Val Ser
Lys Leu Ser Val
Lys Leu Val Ser
Lys Ser Ile Val
Lys Ser Leu Val
Lys Ser Val Ile
Lys Ser Val Leu
Lys Thr Val Val
Lys Val Ile Ser
Lys Val Leu Ser
Lys Val Ser Ile
Lys Val Ser Leu
Lys Val Thr Val
Lys Val Val Thr
Leu Lys Ser Val
Leu Lys Val Ser
Leu Ser Lys Val
Leu Ser Val Lys
Leu Val Lys Ser
Leu Val Ser Lys
Ser Ile Lys Val
Ser Ile Val Lys
Ser Lys Ile Val
Ser Lys Leu Val
Ser Lys Val Ile
Ser Lys Val Leu
Ser Leu Lys Val
Ser Leu Val Lys
Ser Val Ile Lys
Ser Val Lys Ile
Ser Val Lys Leu
Ser Val Leu Lys
Thr Lys Val Val
Thr Val Lys Val
Thr Val Val Lys
Val Ile Lys Ser
Val Ile Ser Lys
Val Lys Ile Ser
Val Lys Leu Ser
Val Lys Ser Ile
Val Lys Ser Leu
Val Lys Thr Val
Val Lys Val Thr
Val Leu Lys Ser
Val Leu Ser Lys
Val Ser Ile Lys
Val Ser Lys Ile
Val Ser Lys Leu
Val Ser Leu Lys
Val Thr Lys Val
Val Thr Val Lys
Val Val Lys Thr
Val Val Thr Lys
N-[(2R)-2-[4-(1H-indol-4-yl)-1-piperazinyl]propyl]-N-(2-pyridinyl)cyclohexanecarboxamide
1-[(8R,9R,10R)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
1-[(8S,9R,10R)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
1-[(8S,9S,10S)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
1-[(8R,9S,10R)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
1-[(8S,9R,10S)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
1-[(8R,9S,10S)-10-(hydroxymethyl)-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(2-pyridinyl)ethanone
(4E,8E)-3-hydroxy-2-(undecanoylamino)dodeca-4,8-diene-1-sulfonic acid
C23H43NO5S (445.2861788000001)
(4E,8E)-2-(decanoylamino)-3-hydroxytrideca-4,8-diene-1-sulfonic acid
C23H43NO5S (445.2861788000001)
(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]dec-4-ene-1-sulfonic acid
C23H43NO5S (445.2861788000001)